Markets

Insider Trading

Hedge Funds

Retirement

Opinion

15 Best Biotech Penny Stocks to Invest in Right Now

Page 1 of 13

In this article, we will be taking a look at the 15 Best Biotech Penny Stocks to Invest in Right Now.

Jared Holz, the healthcare strategist for Mizuho, spoke on CNBC’s “Closing Bell Overtime” in July on whether the biotech industry is ready for a breakthrough. Given that there are hundreds of publicly traded stocks that don’t amount to anything overall, he said that the biotech industry has been a “super tough sector” in any case. He went on to say that it is difficult to make an industrial decision because there are many advantages and disadvantages.

But after “indiscriminately trading horribly for so long,” Holz said he thinks the sector is trading “a little bit better” now that it has stopped declining daily.

He reasoned that it is time for a move higher because all the disadvantages, such as pricing pressures and competition in the quantity of assets in the publicly listed arena, are now fully recognized and absorbed. “It would definitely be a less negative move, even though it might not be a huge one,” Holz said.

With these trends in view, let’s look at the best biotech penny stocks to invest in right now.

Our Methodology 

For our methodology, we first screened biotech stocks trading below $5 per share and showing positive year-to-date (YTD) returns. From this pool, we selected the top 15 stocks with the strongest YTD performance as of September 19. Finally, we ranked these stocks in ascending order based on their YTD returns.

Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter’s strategy selects 14 small-cap and large-cap stocks every quarter and has returned 373.4% since May 2014, beating its benchmark by 218 percentage points (see more details here).

Here is our list of the 15 best biotech penny stocks to invest in right now.  

15. Hoth Therapeutics, Inc. (NASDAQ:HOTH)

Year-to-Date Return: 140.64% 

Hoth Therapeutics, Inc. (NASDAQ:HOTH) is advancing next-generation therapies across dermatology, oncology, and neurology, with a robust pipeline that includes proprietary platforms like BioLexa for antimicrobials and HT-ALZ for neurodegenerative conditions. The company focuses on innovative solutions for unmet medical needs, including eczema, chronic wounds, mast cell cancers, and neuroinflammation. The stock stands fifteenth on our list among the best penny stocks. 

In September 2025, Hoth Therapeutics, Inc. (NASDAQ:HOTH) announced key developments across its programs. HT-001, a topical therapy for skin toxicities caused by EGFR inhibitor cancer treatments, is expanding globally with a Clinical Trial Application submitted to the European Medicines Agency. European enrollment is expected to begin in early 2026, supplementing ongoing U.S. trials and addressing a significant unmet need.

Meanwhile, HT-KIT, targeting rare mast cell cancers, completed its Good Laboratory Practice (GLP) bioanalytical phase and is moving into formal toxicology studies, meeting crucial regulatory milestones. The business also launched a veteran obesity program, entering metabolic disorder research and strengthening its pipeline through strategic collaborations.

On the financial front, Hoth Therapeutics, Inc. (NASDAQ:HOTH) is taking a progressive approach by expanding its treasury reserve to include up to $1 million in Bitcoin, Ethereum, and Solana, signaling a focus on asset diversification and innovative capital management.

14. Tiziana Life Sciences Ltd (NASDAQ:TLSA)

Year-to-Date Return: 160.0% 

Tiziana Life Sciences Ltd (NASDAQ:TLSA) is a clinical-stage biotech company focused on next-generation immunomodulation therapies for neuroinflammatory and neurodegenerative diseases, including multiple sclerosis, Alzheimer’s, and multiple system atrophy. Its lead candidate, intranasal foralumab, is a fully human anti-CD3 monoclonal antibody designed to stimulate regulatory T cells and rebalance immune function.

In September 2025, Tiziana Life Sciences Ltd (NASDAQ:TLSA) drew attention with significant insider activity. CEO Ivor Elrifi purchased 193,848 shares at $1.65 each, while Executive Chairman Gabriele Cerrone added 25,000 shares, raising his stake to 36.28%. These moves underscore strong management confidence in the corporation’s pipeline and long-term prospects.

Tiziana Life Sciences Ltd (NASDAQ:TLSA) also secured a U.S. Department of Defense grant on September 15, 2025, to accelerate intranasal foralumab development for spinal cord injury, expanding its immunomodulatory focus beyond central nervous system disorders. Clinically, the business reached a milestone with the dosing of the first patient in a Phase 2a trial for multiple system atrophy, following FDA approval of a Phase 2 IND application in August 2025.

13. Invivyd, Inc. (NASDAQ:IVVD)

Year-to-Date Return: 175.40% 

Invivyd, Inc. (NASDAQ:IVVD) is a commercial-stage biopharmaceutical company focused on developing antibody-based therapies for serious viral infections, including COVID-19 and influenza. Its INVYMAB platform combines viral surveillance, predictive modeling, and advanced antibody engineering to deliver next-generation monoclonal antibody (mAb) solutions.

Recently, Invivyd, Inc. (NASDAQ:IVVD) announced a strategic agreement with the FDA to use a single Phase 2/3 trial as the pivotal study supporting full approval of its lead COVID-19 mAb candidate, VYD2311. This streamlined Biologics License Application (BLA) pathway positions VYD2311 as a front-runner in adaptable COVID-19 therapies, capable of addressing both prevention and emerging variants.

The firm also strengthened its financial position with a $57.5 million public offering, issuing over 89 million shares. Proceeds will fund the continued development of VYD2311 and the expansion of its infectious disease pipeline, including influenza and other viral threats. Investor confidence surged, driving the stock up more than 90%, making it one of the best penny stocks to watch in the biotech sector.

Further validating its pipeline, Invivyd, Inc. (NASDAQ:IVVD)’s VYD2311 was highlighted in the SPEAR Study Group’s recommended Long COVID antibody study design at the RECOVER-TLC Workshop, reflecting growing recognition of its potential beyond prevention.

Page 1 of 13

AI, Tariffs, Nuclear Power: One Undervalued Stock Connects ALL the Dots (Before It Explodes!)

Artificial intelligence is the greatest investment opportunity of our lifetime. The time to invest in groundbreaking AI is now, and this stock is a steal!

AI is eating the world—and the machines behind it are ravenous.

Each ChatGPT query, each model update, each robotic breakthrough consumes massive amounts of energy. In fact, AI is already pushing global power grids to the brink.

Wall Street is pouring hundreds of billions into artificial intelligence—training smarter chatbots, automating industries, and building the digital future. But there’s one urgent question few are asking:

Where will all of that energy come from?

AI is the most electricity-hungry technology ever invented. Each data center powering large language models like ChatGPT consumes as much energy as a small city. And it’s about to get worse.

Even Sam Altman, the founder of OpenAI, issued a stark warning:

“The future of AI depends on an energy breakthrough.”

Elon Musk was even more blunt:

“AI will run out of electricity by next year.”

As the world chases faster, smarter machines, a hidden crisis is emerging behind the scenes. Power grids are strained. Electricity prices are rising. Utilities are scrambling to expand capacity.

And that’s where the real opportunity lies…

One little-known company—almost entirely overlooked by most AI investors—could be the ultimate backdoor play. It’s not a chipmaker. It’s not a cloud platform. But it might be the most important AI stock in the US owns critical energy infrastructure assets positioned to feed the coming AI energy spike.

As demand from AI data centers explodes, this company is gearing up to profit from the most valuable commodity in the digital age: electricity.

The “Toll Booth” Operator of the AI Energy Boom

  • It owns critical nuclear energy infrastructure assets, positioning it at the heart of America’s next-generation power strategy.
  • It’s one of the only global companies capable of executing large-scale, complex EPC (engineering, procurement, and construction) projects across oil, gas, renewable fuels, and industrial infrastructure.
  • It plays a pivotal role in U.S. LNG exportation—a sector about to explode under President Trump’s renewed “America First” energy doctrine.

Trump has made it clear: Europe and U.S. allies must buy American LNG.

And our company sits in the toll booth—collecting fees on every drop exported.

But that’s not all…

As Trump’s proposed tariffs push American manufacturers to bring their operations back home, this company will be first in line to rebuild, retrofit, and reengineer those facilities.

AI. Energy. Tariffs. Onshoring. This One Company Ties It All Together.

While the world is distracted by flashy AI tickers, a few smart investors are quietly scooping up shares of the one company powering it all from behind the scenes.

AI needs energy. Energy needs infrastructure.

And infrastructure needs a builder with experience, scale, and execution.

This company has its finger in every pie—and Wall Street is just starting to notice.

Wall Street is noticing this company also because it is quietly riding all of these tailwinds—without the sky-high valuation.

While most energy and utility firms are buried under mountains of debt and coughing up hefty interest payments just to appease bondholders…

This company is completely debt-free.

In fact, it’s sitting on a war chest of cash—equal to nearly one-third of its entire market cap.

It also owns a huge equity stake in another red-hot AI play, giving investors indirect exposure to multiple AI growth engines without paying a premium.

And here’s what the smart money has started whispering…

The Hedge Fund Secret That’s Starting to Leak Out

This stock is so off-the-radar, so absurdly undervalued, that some of the most secretive hedge fund managers in the world have begun pitching it at closed-door investment summits.

They’re sharing it quietly, away from the cameras, to rooms full of ultra-wealthy clients.

Why? Because excluding cash and investments, this company is trading at less than 7 times earnings.

And that’s for a business tied to:

  • The AI infrastructure supercycle
  • The onshoring boom driven by Trump-era tariffs
  • A surge in U.S. LNG exports
  • And a unique footprint in nuclear energy—the future of clean, reliable power

You simply won’t find another AI and energy stock this cheap… with this much upside.

This isn’t a hype stock. It’s not riding on hope.

It’s delivering real cash flows, owns critical infrastructure, and holds stakes in other major growth stories.

This is your chance to get in before the rockets take off!

Disruption is the New Name of the Game: Let’s face it, complacency breeds stagnation.

AI is the ultimate disruptor, and it’s shaking the foundations of traditional industries.

The companies that embrace AI will thrive, while the dinosaurs clinging to outdated methods will be left in the dust.

As an investor, you want to be on the side of the winners, and AI is the winning ticket.

The Talent Pool is Overflowing: The world’s brightest minds are flocking to AI.

From computer scientists to mathematicians, the next generation of innovators is pouring its energy into this field.

This influx of talent guarantees a constant stream of groundbreaking ideas and rapid advancements.

By investing in AI, you’re essentially backing the future.

The future is powered by artificial intelligence, and the time to invest is NOW.

Don’t be a spectator in this technological revolution.

Dive into the AI gold rush and watch your portfolio soar alongside the brightest minds of our generation.

This isn’t just about making money – it’s about being part of the future.

So, buckle up and get ready for the ride of your investment life!

Act Now and Unlock a Potential 100+% Return within 12 to 24 months.

We’re now offering month-to-month subscriptions with no commitments.

For a ridiculously low price of just $9.99 per month, you can unlock our in-depth investment research and exclusive insights – that’s less than a single fast food meal!

Space is Limited! Only 1000 spots are available for this exclusive offer. Don’t let this chance slip away – subscribe to our Premium Readership Newsletter today and unlock the potential for a life-changing investment.

Here’s what to do next:

1. Head over to our website and subscribe to our Premium Readership Newsletter for just $9.99.

2. Enjoy a month of ad-free browsing, exclusive access to our in-depth report on the Trump tariff and nuclear energy company as well as the revolutionary AI-robotics company, and the upcoming issues of our Premium Readership Newsletter.

3. Sit back, relax, and know that you’re backed by our ironclad 30-day money-back guarantee.

Don’t miss out on this incredible opportunity! Subscribe now and take control of your AI investment future!


No worries about auto-renewals! Our 30-Day Money-Back Guarantee applies whether you’re joining us for the first time or renewing your subscription a month later!

A New Dawn is Coming to U.S. Stocks

I work for one of the largest independent financial publishers in the world – representing over 1 million people in 148 countries.

We’re independently funding today’s broadcast to address something on the mind of every investor in America right now…

Should I put my money in Artificial Intelligence?

Here to answer that for us… and give away his No. 1 free AI recommendation… is 50-year Wall Street titan, Marc Chaikin.

Marc’s been a trader, stockbroker, and analyst. He was the head of the options department at a major brokerage firm and is a sought-after expert for CNBC, Fox Business, Barron’s, and Yahoo! Finance…

But what Marc’s most known for is his award-winning stock-rating system. Which determines whether a stock could shoot sky-high in the next three to six months… or come crashing down.

That’s why Marc’s work appears in every Bloomberg and Reuters terminal on the planet…

And is still used by hundreds of banks, hedge funds, and brokerages to track the billions of dollars flowing in and out of stocks each day.

He’s used this system to survive nine bear markets… create three new indices for the Nasdaq… and even predict the brutal bear market of 2022, 90 days in advance.

Click to continue reading…